Hexarelin has controlled human pharmacology data, but the central evidence is an acute 12-person GH dose-response experiment rather than a clinical-outcome trial.
Evidence at a glance
- Twelve healthy men received placebo and 0.5, 1 and 2 µg/kg intravenous Hexarelin in a double-blind rising-dose study.
- Mean peak GH was 3.9, 26.9, 52.3 and 55.0 ng/mL, with a response plateau between 1 and 2 µg/kg.
- GH peaked at about 30 minutes, returned to baseline within 240 minutes and had an estimated half-life near 55 minutes.
Study record
The 1994 study inserted placebo randomly into the rising-dose sequence. The near-identical mean peaks at 1 and 2 µg/kg are a useful plateau finding and should not be rewritten as “higher is always better.”
Results in context
A later six-person study compared two versus three daily subcutaneous administrations while monitoring GH, prolactin, ACTH and cortisol over 24 hours. Multiple endocrine changes reinforce that Hexarelin cannot be reduced to a selective GH-only claim.
WADA lists Examorelin/Hexarelin among prohibited GH-releasing peptides. That classification is relevant to sport but does not establish efficacy or product identity.
What the evidence cannot establish
The primary trial had 12 healthy male participants and acute endpoints.
No body-composition, recovery, disease or long-term safety outcome was measured.
Endocrine response from a defined experimental material cannot validate a catalog lot.
Sources & editorial method
This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.
4 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, sample size, model/population limits, finished-drug scope, regulatory status and product-evidence boundaries are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Hexarelin human dose-response studyDouble-blind 12-person study; PMID 7957536.
- Repeated Hexarelin administration in healthy menSix-person 24-hour endocrine study; PMID 11888836.
- PubChem Examorelin recordSequence, formula, molecular weight and synonyms; CID 6918297.
- WADA 2026 Prohibited ListOfficial list prohibits mechano growth factors.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
